Globally, the availability and delivery of cognitive pharmaceutical services (CPS) by pharmacists has expanded over time. Australia has been no exception to this trend, with government funding to support the provision of certain CPS significantly increasing over the last two decades. Whilst medication management services have been consistently funded by the government for more than 15 years, fluctuations in the funding of other CPS have been observed; for example, certain disease state management CPS and introduction of funded MedsChecks. Furthermore, legislative changes have broadened pharmacists’ scope of practice and the CPS provided, contributing to an increase in user-pay services. Although the literature to date has highlighted positive impacts associated with CPS on economic, clinical and/or humanistic outcomes, context-specific, real world evidence for the benefits of CPS is much needed to ensure the profession engages in evidence-based practice. The aim of this commentary is to outline the changes in CPS provision and funding within the Australian context, the existing evidence for CPS, and highlight the implications for future research.

在全球范围内，药剂师认知药物服务 (CPS) 的可用性和交付随着时间的推移而扩大。澳大利亚也不例外，在过去的二十年里，政府为支持提供某些 CPS 提供的资金显着增加。虽然药物管理服务一直由政府资助超过 15 年，但观察到其他 CPS 的资金波动；例如，某些疾病状态管理 CPS 和引入资助的 MedsChecks。此外，立法变化扩大了药剂师的执业范围和提供的 CPS，有助于增加用户付费服务。尽管迄今为止的文献强调了与 CPS 相关的对经济、临床和/或人文结果的积极影响，但具体情况，非常需要真实世界的证据证明 CPS 的好处，以确保该专业从事循证实践。本评论的目的是概述澳大利亚背景下 CPS 提供和资助的变化、CPS 的现有证据，并强调对未来研究的影响。